TROLIP Capsule

Trolip is indicated to treatment:

- Hypercholesterolemia (typeⅡa).

- Hypertriglyceridemia (typeⅣ).

- Mix hyperlipidemia (typeⅡb and Ⅲ).

Dosage and administration:

Adults

Initial dose: 100mg 3 times a day or 300mg/day as a single dose.

If after strict cholesterol diet the concentration of cholesterol stays at > 4g/L, dose can be increased to 100mg 4 times daily.

Initial dose should be maintained until cholesterol level gets back to normal. If cholesterol level is stabilized, dosage of 100mg twice daily can be given provided that cholesterol level is checked every 3 months. If there is a new increase in the plasma cholesterol concentration, dose should go back to initial dose of 100mg 3 times daily.

Children

Over 10 years: maximum 5mg/kg daily.

- Patients with severe liver and renal dysfunction.

- Pregnancy and lactation.

- Hypersensitivity to fenofibrate.

- Patients with gallbladder disease.

In general, side effects are mid and rarely reported. In prolonged therapy, the following side effects have been reported:

- Gastrointestinal disturbances about 5%.

- Headache about 1%.

- Muscular spasm about 1%.

- Transient elevation of transaminases and creatin phosphokinase.

- Skin allergic reactions.

- Fatigue and vertigo.

The effect of oral anticoagulant is potentiated by fenofibrate. This increase the risk of haemorrhage through displacement of their binding with plasma protein. Therefore, initial dose therapy with fenofibrate should be reduced to 1/3 of the normal dose. Adjustment of oral anticoagulant dose according to prothrombin time during therapy by fenofibrate and 8 days after its interruption.

See "Contraindication".

- For the first year of therapy, serum transaminase should be monitored periodically, every 3 months. Therapy should be discontinue if there is an increase in SGPT concentration >100unit/L.

- Combination therapy of hepatotoxic substances like perheccillin maleate or IMAO is not recommended.

- If 3 months after therapy, the reduction of serum concentration of lipid is not satisfactory, other therapeutic) complementary or different) should be considered.

Fenofibrate is phyenoxyisobutyric acid. With clofibrate and other fibrate acid derivatives is used as lipid regulator by reducing total plasma cholesterol and triglyceride in healthy subjects and patients with Hyperlipoproteinemia. The main action of fenofibrate is to increase lipoprotein catabolism which is risk in triglyceride by increasing lipase lipoprotein activity.